AtriCure (NASDAQ:ATRC) Director Maggie Yuen Sells 3,000 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,000 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the transaction, the director directly owned 11,371 shares of the company’s stock, valued at $406,172.12. This trade represents a 20.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded up $0.02 on Tuesday, hitting $37.76. The company’s stock had a trading volume of 45,583 shares, compared to its average volume of 549,701. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -61.89 and a beta of 1.56. AtriCure, Inc. has a 12 month low of $28.29 and a 12 month high of $43.11. The stock’s 50-day moving average is $35.07 and its two-hundred day moving average is $34.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.10. The business had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The company’s revenue was up 15.8% compared to the same quarter last year. During the same period last year, the company posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, equities research analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the topic of a number of recent analyst reports. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Thursday, October 30th. Needham & Company LLC lifted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. Canaccord Genuity Group increased their price objective on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, BTIG Research set a $54.00 price target on shares of AtriCure in a research report on Wednesday, July 30th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $52.22.

Hedge Funds Weigh In On AtriCure

Several large investors have recently added to or reduced their stakes in ATRC. Ameritas Investment Partners Inc. raised its holdings in shares of AtriCure by 6.7% in the second quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock valued at $162,000 after buying an additional 312 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of AtriCure by 6.5% in the third quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock worth $218,000 after acquiring an additional 380 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of AtriCure by 5.4% during the second quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after purchasing an additional 385 shares in the last quarter. Scotia Capital Inc. increased its holdings in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after purchasing an additional 457 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd increased its stake in AtriCure by 197.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 538 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.